Why the CSL share price is touching $200 again

Will CSL Limited (ASX: CSL) outperform the market for the next 5 years?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price printed as high as $199.75 this morning and is just a whisker off the psychologically important $200 mark despite the healthcare giant releasing no news to the market.

On January 1 2019 I made CSL my top stock pick for January,when it sold for $185.38 which means it's up around 8% since then and roughly in line with the market.

However, I expect over the medium term it will go on to thump the market's returns despite today's lofty valuation.

This is because CSL is one of not-too-many businesses on the local market that are able to consistently grow profits while investing heavily in the growth products of tomorrow.

The consistent profit growth comes about thanks to the moat provided by the complexity of its healthcare products that also provide it some pricing power.

Its return on invested capital is also 25.9% which thumps the returns of most of its blue-chip share peers and partly explains why the company is able to consistently outperform the market.

Should I buy?

On a trailing FX-adjusted basis CSL earned A$5.40 per share in FY 2018 to put it on 37x trailing earnings.

However, this shows us next to nothing, as it's the full year result for FY 2019 that counts, with the group forecasting profit growth around 14% while investing up to US$200 million in research and development.

In my opinion CSL shares are a buy at today's valuation, while other leaders in the healthcare space such as Cochlear Ltd (ASX: COH), Ramsay Health Care Limited (ASX: RHC) and ResMed Inc. (ASX: RMD) also trade on high valuations likely to divide investors as to their worth.

However, CSL is probably the best-performing blue-chip growth stock on the S&P/ ASX200 (ASX: XJO) over the past 5 years and probably longer.

Motley Fool contributor Tom Richardson owns shares of Cochlear Ltd., CSL Ltd., and ResMed Inc. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has recommended Cochlear Ltd., Ramsay Health Care Limited, and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »